All In Biotech

Drug Trial Radar · NCT03600883

A Phase 1/2, Study Evaluating the Safety, Tolerability, PK, and Efficacy of Sotorasib (AMG 510) in Subjects With Solid Tumors With a Specific KRAS Mutation (CodeBreaK 100)

A Phase 1/2, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of Sotorasib (AMG 510) Monotherapy in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation and Sotorasib (AMG 510) Combination Therapy in Subjects With Advanced NSCLC With KRAS p.G12C Mutation (CodeBreaK 100)

Last checked: Nov 20, 2026Latest source record: Jun 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 713 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

713

Actual

Start

Aug 27, 2018

Primary completion

May 29, 2026

Study completion May 29, 2026

Sponsor

Lead sponsor
AmgenAmgen (AMGN)
Sponsor type
Industry
First posted
Jul 26, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 100 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Evaluate the safety and tolerability of sotorasib in adult subjects with KRAS p.G12C mutant advanced solid tumors. Estimate the maximum tolerated dose (MTD) and/or a recommended phase 2 dose (RP2D) in adult subjects with KRAS p.G12C mutant advanced solid tumors.

Conditions

  • KRAS p.G12C Mutant Advanced Solid Tumors

Interventions

  • sotorasibDrug

    Characterize the pharmacokinetics (PK) of sotorasib following administration as an oral Tablet formulation

  • Anti PD-1/L1Drug

    Administered as an intravenous (IV) infusion

  • MidazolamDrug

    Administered as an oral hydrochloride (HCI) syrup

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Primary: Number of subjects with treatment-emergent adverse eventsTime frame: 24 Months
  2. Primary: Number of subjects with treatment-related adverse eventsTime frame: 24 Months
  3. Primary: Number of subjects with grade ≥3 treatment-emergent adverse eventsTime frame: 24 Months
  4. Primary: Number of subjects with serious adverse eventsTime frame: 24 Months
  5. Primary: Number of subjects with adverse events of interestTime frame: 24 Months
  6. Primary: Number of subjects with clinically significant changes in vital signsTime frame: Baseline to 24 Months
  7. Primary: Number of subjects with clinically significant changes in physical examination resultsTime frame: Baseline to 24 Months
  8. Primary: Number of subjects with clinically significant changes on electrocardiograms (ECGs)Time frame: Baseline to 24 Months
  9. Primary: Number of subjects with clinically significant changes in clinical laboratory valuesTime frame: Baseline to 24 Months
  10. Primary: Number of subjects with dose-limiting toxicities (DLTs)Time frame: 21 Days
  11. Primary: Objective response rate (ORR) as assessed by RECIST 1.1 criteriaTime frame: 24 Months
  12. Primary: Duration of response (DOR) as assessed by RECIST 1.1 criteriaTime frame: 24 Months
  13. Primary: Disease control as assessed by RECIST 1.1 criteriaTime frame: 24 Months
  14. Primary: Duration of stable disease (SD) as assessed by RECIST 1.1 criteriaTime frame: 24 Months
  15. Primary: Time to response (TTR) as assessed by RECIST 1.1 criteriaTime frame: 24 Months

Locations

133 sites in 16 countries. Site status is shown where the registry gives one.

  • City of Hope National Medical Center

    Duarte, California

  • University of California Los Angeles

    Los Angeles, California

  • University of California at SF

    San Francisco, California

  • Sarcoma Oncology Research Center LLC

    Santa Monica, California

  • Rocky Mountain Cancer Centers

    Denver, Colorado

  • Sarah Cannon Research Institute at HealthONE

    Denver, Colorado

  • Smilow Cancer Hospital at Yale New Haven

    New Haven, Connecticut

  • Medical Oncology Hematology Consultants Helen F Graham Cancer Center

    Newark, Delaware

  • University of Florida Health

    Gainesville, Florida

  • AdventHealth Orlando Infusion Center

    Orlando, Florida

  • Moffitt Cancer Center

    Tampa, Florida

  • Winship Cancer Institute

    Atlanta, Georgia

  • Indiana University

    Indianapolis, Indiana

  • American Oncology Partners of Maryland, PA

    Bethesda, Maryland

  • Massachusetts General Hospital

    Boston, Massachusetts

  • Dana Farber Cancer Institute

    Boston, Massachusetts

  • University of Michigan

    Ann Arbor, Michigan

  • Henry Ford Health System

    Detroit, Michigan

  • Washington University

    St Louis, Missouri

  • Roswell Park Cancer Institute

    Buffalo, New York

  • Laura and Isaac Perlmutter Cancer Center at New York University Langone

    New York, New York

  • Memorial Sloan Kettering Cancer Center

    New York, New York

  • Duke University Medical Center, Morris Cancer Clinic

    Durham, North Carolina

  • University Hospitals Cleveland Medical Center

    Cleveland, Ohio

  • Cleveland Clinic

    Cleveland, Ohio

  • University of Pennsylvania

    Philadelphia, Pennsylvania

  • Fox Chase Cancer Center

    Philadelphia, Pennsylvania

  • University of Pittsburgh Medical Center Cancer Pavillion

    Pittsburgh, Pennsylvania

  • Gibbs Cancer Center and Research Institute - Spartanburg

    Spartanburg, South Carolina

  • Vanderbilt University Ingram Cancer Center

    Nashville, Tennessee

  • Texas Oncology - Austin Central

    Austin, Texas

  • Texas Oncology - Baylor

    Dallas, Texas

  • University of Texas Southwestern Medical Center

    Dallas, Texas

  • University of Texas MD Anderson Cancer Center

    Houston, Texas

  • Huntsman Cancer Institute

    Salt Lake City, Utah

  • US Oncology Research Investigational Products Center

    Fairfax, Virginia

  • Virginia Cancer Specialists PC

    Fairfax, Virginia

  • Blue Ridge Cancer Care

    Salem, Virginia

  • Seattle Cancer Care Alliance

    Seattle, Washington

  • Scientia Clinical Research Ltd

    Randwick, New South Wales, Australia

Showing 40 of 133 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.